Evidence map›Paper›PMID 38157383›Full record

ArticlePloS one2023

Epidemiological characterization of ischemic heart disease at different altitudes: A nationwide population-based analysis from 2011 to 2021 in Ecuador.

Esteban Ortiz-Prado, Juan S Izquierdo-Condoy, Raúl Fernández-Naranjo, Jorge Vásconez-González, Leonardo Cano, Ana Carolina González, Estefanía Morales-Lapo, Galo S Guerrero-Castillo, Erick Duque, Maria Gabriela Davila Rosero and 2 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Esteban Ortiz-PradoOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.ORCID 0000-0002-1895-7498
Juan S Izquierdo-CondoyOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.
Raúl Fernández-NaranjoOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.
Jorge Vásconez-GonzálezOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.
Leonardo CanoOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.ORCID 0000-0002-2469-0777
Ana Carolina GonzálezOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.
Estefanía Morales-LapoOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.
Galo S Guerrero-CastilloOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.
Erick DuqueOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.
Maria Gabriela Davila RoseroOne Health Research Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador.ORCID 0000-0002-1367-1845
Diego EgasDepartamento de Cardiología, Hospital Metropolitano, Quito, Ecuador.
Ginés ViscorDepartament de Biología Cel·lular, Fisiologia i Immunologia, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-4942-2346

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular diseases, including ischemic heart disease, are the leading cause of premature death and disability worldwide. While traditional risk factors such as smoking, obesity, and diabetes have been thoroughly investigated, non-traditional risk factors like high-altitude exposure remain underexplored. This study aims to examine the incidence and mortality rates of ischemic heart disease over the past decade in Ecuador, a country with a diverse altitude profile spanning from 0 to 4,300 meters.

methodsWe conducted a geographic distribution analysis of ischemic heart disease in Ecuador, utilizing hospital discharge and mortality data from the National Institute of Census and Statistics for the years 2011-2021. Altitude exposure was categorized according to two distinct classifications: the traditional division into low (< 2,500 m) and high (> 2,500 m) altitudes, as well as the classification proposed by the International Society of Mountain Medicine, which delineates low (< 1,500 m), moderate (1,500-2,500 m), high (2,500-3,500 m), and very high (3,500-5,800 m) altitudes.

findingsFrom 2011-2021, we analyzed 49,765 IHD-related hospital admissions and 62,620 deaths. Men had an age-adjusted incidence rate of 55.08/100,000 and a mortality rate of 47.2/100,000, compared to 20.77/100,000 and 34.8/100,000 in women. Incidence and mortality surged in 2020 by 83% in men and 75% in women. Altitudinal stratification revealed higher IHD rates at lower altitudes (<2500 m), averaging 61.65 and 121.8 per 100,000 for incidence and mortality, which declined to 25.9 and 38.5 at elevations >2500 m. Men had more pronounced rates across altitudes, exhibiting 138.7% and 150.0% higher incidence at low and high altitudes respectively, and mortality rates increased by 48.3% at low altitudes and 23.2% at high altitudes relative to women.

conclusionEcuador bears a significant burden of ischemic heart disease (IHD), with men being more affected than women in terms of incidence. However, women have a higher percentage of mortality post-hospital admission. Regarding elevation, our analysis, using two different altitude cutoff points, reveals higher mortality rates in low-altitude regions compared to high-altitude areas, suggesting a potential protective effect of high elevation on IHD risk. Nevertheless, a definitive dose-response relationship between high altitude and reduced IHD risk could not be conclusively established.

Indexed as

AltitudeMyocardial IschemiaEcuadorFemaleHumansMaleRisk FactorsSmoking

Identifiers

PMID38157383
PMCPMC10756509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.